Toronto, Ontario – TheNewswire – November 4, 2022 – Ventripoint Diagnostics Ltd (“ventripoint“or the”Company“), (TSX V: VPT); (OTC: VPTDF) is pleased to announce that it will be the Gold Sponsor of the 2022 British Congenital Cardiac Association (BCCA) Annual Scientific Meeting. Dr. Gregory Skinner, the company’s clinical advisor, will deliver a presentation that will highlight the use of VMS+3.0 in volumetric and functional data retrieval for the management of cardiac patients.
The meeting will take place on Monday 7e and Tuesday 8e November 2022 at the Birmingham International Conference Centre, UK. The BCCA meeting attracts over 400 delegates from across the UK and around the world with a focus on adult and pediatric congenital cardiology. Attendees will be members of various cardiac associations and medical professionals, creating a valuable networking experience each year.
Dr. Skinner’s presentation will take place on November 8e, 2022 and is titled: “Accurate and reproducible volumetric and functional data for the management of congenital heart disease using Ventripoint’s VMS”. The presentation will focus on the unique capabilities of VMS+3.0 in managing congenital heart patients through case studies and real world examples.
Exhibiting at the BCCA Meeting continues Ventripoint’s ongoing efforts to educate the cardiology community about the benefits of VMS+ 3.0 and allow them to have hands-on experience of the ease of use of the system in the exhibit booth and then schedule a on-site demonstration at their clinic.
About Ventripoint Diagnostics Ltd.
ventripoint has become an industry leader in the application of AI (artificial intelligence) to echocardiography. Ventripoint’s VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable and reference alternative allows cardiologists to have greater confidence in the care of their patients. Providing better patient care serves as the springboard and baseline standard for all Ventripoint products that guide our future developments. Additionally, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by market regulatory approvals in the US, Europe and Canada.
For more information, please contact:
Dr. George Adams
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Forward Looking for statements
This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. Use of any of the words “expect”, “anticipate”, “continue”, “estimate”, “target”, “ongoing”, “may”, “will”, “plan”, ” should”, “believe”, “plans”, “intends” and similar expressions are intended to identify forward-looking information or statements. Forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which these forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information as the Company cannot guarantee that they will prove to be accurate.
Because forward-looking statements and information relate to future events and conditions, they, by their very nature, involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors that could materially affect such forward-looking information are described in the Company’s most recent annual MD&A risk factors available on the Company’s profile on SEDAR at www.sedar.com. Readers are cautioned that the above list of factors is not exhaustive. The forward-looking statements included in this press release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this press release are made as of the date hereof, and the Company undertakes no obligation to publicly update or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise. , except as required by applicable securities laws.
#Ventripoint #sponsor #annual #meeting #British #Congenital #Cardiac #Association